Welcome to the Hardcore Husky Forums. Folks who are well-known in Cyberland and not that dumb.
Maximum Carnage Week Game Thread
Comments
-
I actually did pick up on that. But n = 500 was a more efficient attack vector as I speed down the freeway doing blow of a hookers ass.GrundleStiltzkin said:
I thought you'd pick up on the fact the study seems to involve people already hospitalized or otherwise under medical care, that is sick people. If I remember right, you guysm take it prophylactically. Regardless, appears to be reasonably well-executed study for what it was intended.pawz said:
n = 500GrundleStiltzkin said:Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Key Points
Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Enough said about that.
I even looked up the FLCCC recommendations and noted they used 50% more dosing than this study. .4mg/kg vs .6mg/kg for the already hospitalized*.
*If you remember early Jan there was the very public female doctor blasting her hospital in the media. She notoriously used 20x that dosing of IVM on her patients - to great effect and the ire of her hospital.
-
Bullshit. "Meaning" is meaningless without defining "high risk."GrundleStiltzkin said:Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Key Points
Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Shit study. C'mon Man! -
Funny it sure works in India, Africa etc.
-
That’s because people there are animals!Sledog said:Funny it sure works in India, Africa etc.
-
MikeDamone said:
That’s because people there are animals!Sledog said:Funny it sure works in India, Africa etc.
-
Good thing we aren't fracking on federal lands and exporting LNG to the chicoms and Europe. Cho Bai Den has helped double the price of oil to the great benefit of Putin. Leftards voted for this sh*t and think that makes them a better smarter person. Geezus.
https://instapundit.com/
CHINA WANTS TO BUY 100 MILLION METRIC TONS OF COAL FROM RUSSIA.
Via Small Dead Animals, which asks, “Any response from Greta yet?” -
I know half a dozen close friends who beat the vid by taking horse paste.Sledog said:Funny it sure works in India, Africa etc.
-
I think that was the intent. It probably is more difficult to study giving it to people and then getting them infected with COVID. It's much easier to design a study with outcome in mind.GrundleStiltzkin said:
I thought you'd pick up on the fact the study seems to involve people already hospitalized or otherwise under medical care, that is sick people. If I remember right, you guysm take it prophylactically. Regardless, appears to be reasonably well-executed study for what it was intended.pawz said:
n = 500GrundleStiltzkin said:Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities
Key Points
Question Does adding ivermectin, an inexpensive and widely available antiparasitic drug, to the standard of care reduce the risk of severe disease in patients with COVID-19 and comorbidities?
Findings In this open-label randomized clinical trial of high-risk patients with COVID-19 in Malaysia, a 5-day course of oral ivermectin administered during the first week of illness did not reduce the risk of developing severe disease compared with standard of care alone.
Meaning The study findings do not support the use of ivermectin for patients with COVID-19.
Enough said about that.
-
